Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Terns Pharmaceuticals ( (TERN) ) has shared an update.
On February 1, 2025, Terns Pharmaceuticals, Inc. announced the resignation of Chief Financial Officer Mark Vignola, Ph.D., as per the Vignola Transition Agreement. His departure was amicable and followed by a consulting arrangement, allowing Dr. Vignola to continue contributing as an independent contractor until July 31, 2025. Amy Burroughs, the Chief Executive Officer, assumed the role of principal financial officer, and David Strauss, Vice President of Finance and Controller, took on the position of principal accounting officer on an interim basis. This transition aims to ensure continuity in the company’s financial leadership.
More about Terns Pharmaceuticals
YTD Price Performance: -17.81%
Average Trading Volume: 1,828,554
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $395.8M
For an in-depth examination of TERN stock, go to TipRanks’ Stock Analysis page.
